Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Uromitexan 1g/10ml solution for injection ampoules
0801000T0BBABAB
|
Uromitexan | Mesna | Malignant Disease and Immunosuppression | No data available |
|
Uromitexan 400mg tablets
0801000T0BBADAC
|
Uromitexan | Mesna | Malignant Disease and Immunosuppression | No data available |
|
Uromitexan 400mg/4ml solution for injection ampoules
0801000T0BBAAAA
|
Uromitexan | Mesna | Malignant Disease and Immunosuppression | No data available |
|
Uromitexan 600mg tablets
0801000T0BBAEAD
|
Uromitexan | Mesna | Malignant Disease and Immunosuppression | No data available |
|
Uxil 110.6mg tablets
0801050ANBCAEAL
|
Uxil | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Uxil 15.8mg tablets
0801050ANBCAAAH
|
Uxil | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Uxil 39.5mg tablets
0801050ANBCABAI
|
Uxil | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Uxil 63.2mg tablets
0801050ANBCACAJ
|
Uxil | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Uxil 79.0mg tablets
0801050ANBCADAK
|
Uxil | Dasatinib | Malignant Disease and Immunosuppression | No data available |
|
Vandetanib 100mg tablets
0801050BGAAAAAA
|
Vandetanib | Vandetanib | Malignant Disease and Immunosuppression | No data available |
|
Vandetanib 300mg tablets
0801050BGAAABAB
|
Vandetanib | Vandetanib | Malignant Disease and Immunosuppression | No data available |
|
Vanflyta 17.7mg tablets
0801050CTBBAAAA
|
Vanflyta | Quizartinib | Malignant Disease and Immunosuppression | No data available |
|
Vanflyta 26.5mg tablets
0801050CTBBABAB
|
Vanflyta | Quizartinib | Malignant Disease and Immunosuppression | No data available |
|
Vantas 50mg implant with implantation device
0803042Q0BBAAAA
|
Vantas | Histrelin acetate | Malignant Disease and Immunosuppression | No data available |
|
Vargatef 100mg capsules
0801050BTBBAAAA
|
Vargatef | Nintedanib | Malignant Disease and Immunosuppression | No data available |
|
Vargatef 150mg capsules
0801050BTBBABAB
|
Vargatef | Nintedanib | Malignant Disease and Immunosuppression | No data available |
|
Vectibix 100mg/5ml concentrate for inf vials
0801050ARBBAAAA
|
Vectibix | Panitumumab | Malignant Disease and Immunosuppression | No data available |
|
Vectibix 400mg/20ml concentrate for inf vials
0801050ARBBABAB
|
Vectibix | Panitumumab | Malignant Disease and Immunosuppression | No data available |
|
Vegzelma 100mg/4ml concentrate for inf vials
0801050APBGAAAA
|
Vegzelma | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Vegzelma 400mg/16ml concentrate for inf vials
0801050APBGABAB
|
Vegzelma | Bevacizumab | Malignant Disease and Immunosuppression | No data available |
|
Velbe 10mg powder for solution for injection vials
0801040H0BBAAAA
|
Velbe | Vinblastine sulfate | Malignant Disease and Immunosuppression | No data available |
|
Velcade 3.5mg powder for solution for injection vials
0801050ACBBAAAA
|
Velcade | Bortezomib | Malignant Disease and Immunosuppression | No data available |
|
Vemurafenib 240mg tablets
0801050BDAAAAAA
|
Vemurafenib | Vemurafenib | Malignant Disease and Immunosuppression | No data available |
|
Vepesid 100mg capsules
0801040D0BBABAB
|
Vepesid | Etoposide | Malignant Disease and Immunosuppression | No data available |
|
Vepesid 100mg/5ml solution for infusion vials
0801040D0BBADAD
|
Vepesid | Etoposide | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.